Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium
Standard
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium. / Omar, Muhammad Imran; MacLennan, Steven; Ribal, Maria J; Roobol, Monique J; Dimitropoulos, Konstantinos; van den Broeck, Thomas; MacLennan, Sara J; Axelsson, Susan Evans; Gandaglia, Giorgio; Willemse, Peter-Paul; Mastris, Ken; Ransohoff, John Butler; Devecseri, Zsuzsanna; Abbott, Thomas; De Meulder, Bertrand; Bjartell, Anders; Asiimwe, Alex; N'Dow, James; PIONEER Consortium.
in: NAT REV UROL, Jahrgang 20, Nr. 8, 08.2023, S. 494-501.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Leitlinie, Empfehlung, Stellungnahme › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium
AU - Omar, Muhammad Imran
AU - MacLennan, Steven
AU - Ribal, Maria J
AU - Roobol, Monique J
AU - Dimitropoulos, Konstantinos
AU - van den Broeck, Thomas
AU - MacLennan, Sara J
AU - Axelsson, Susan Evans
AU - Gandaglia, Giorgio
AU - Willemse, Peter-Paul
AU - Mastris, Ken
AU - Ransohoff, John Butler
AU - Devecseri, Zsuzsanna
AU - Abbott, Thomas
AU - De Meulder, Bertrand
AU - Bjartell, Anders
AU - Asiimwe, Alex
AU - N'Dow, James
AU - PIONEER Consortium
AU - Tilki, Derya
N1 - © 2023. Springer Nature Limited.
PY - 2023/8
Y1 - 2023/8
N2 - PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups - health-care professionals and patients with prostate cancer - about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.
AB - PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups - health-care professionals and patients with prostate cancer - about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.
KW - Male
KW - Humans
KW - Consensus
KW - Prostatic Neoplasms/diagnosis
KW - Treatment Outcome
KW - Europe
U2 - 10.1038/s41585-023-00748-9
DO - 10.1038/s41585-023-00748-9
M3 - Guideline, recommendation, statement
C2 - 37012441
VL - 20
SP - 494
EP - 501
JO - NAT REV UROL
JF - NAT REV UROL
SN - 1759-4812
IS - 8
ER -